Patient Details Hidden Show

Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved

Show trials/registries

Form 5: Rejection Episode

Toggle Question Year/Info Print this Form Not Started

1 Select the maintenance immunosuppressive therapy at the time of rejection.

Do not select medications used as treatment for rejection. For example, if on monthly IVIG to prevent recurrence of AMR, that would be OK to select. If given IVIG to treat rejection, do not select IVIG.

- [ ] Azathioprine — REJBIMAZ
- [ ] Cyclosporine — REJBIMCY
- [ ] Everolimus — REJBIMEV
- [ ] Immune globulin — REJBIMIM
- [ ] Methotrexate — REJBIMME
- [ ] Mycophenolate — REJBIMMY
- [ ] Plasmapheresis — REJBIMPL
- [ ] Prednisone — REJBIMPR
- [ ] Rituximab — REJBIMRI
- [ ] Sirolimus — REJBIMSI
- [ ] Tacrolimus — REJBIMTA
- [ ] Cytoxan (cyclophosphamide) — REJBIMCT
- [ ] Unknown — REJBIMUN
- [ ] Other, specify — REJBIMOT

ROIMSP

Question Added: 01 JAN 1993

Biopsy Prior to Rejection Episode

2 Biopsy Performed Prior to Rejection Episode

If performed prior to this rejection diagnosis, indicate the score of the most recent biopsy performed that did not lead to rejection treatment.

- ○ Yes
- ○ No

Question Added: 01 JAN 1993
BIOPPRER

2a Biopsy Date Prior to Rejection Episode

MM/DD/YYYY

Missing Reason:
- ○ Unknown

Question Added: 01 JAN 1993
BIOPDATE

2b ACR Grading

2004 revised ISHLT grading system for ACR: (J Heart Lung Transplant. 2005 Nov;24(11):1710-20.) ACR: acute cellular rejection (0, 1R, 2R, 3R)

- ○ 0R
- ○ 1R
- ○ 2R
- ○ 3R
- ○ Unknown

Question Added: 01 JAN 2010
BIOPSCOR

2c AMR Grading

2013 revised ISHLT grading system for pAMR: J Heart Lung Transplant 2013 Dec 32(12):1147-62.) pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- ○ Both histology and immunofluorescence/ immunohistochemistry performed (ie. C4d or C3d)
- ○ Did not assess biopsy for evidence of AMR
- ○ Only assessed histology/ did not perform immunofluorescence/immunohistochemistry (ie.

PBAMR

C4d or C3d)
- Unknown

Question Added: 07 OCT 2015

2c.i pAMR Grading
2013 revised ISHLT grading system for pAMR:
J Heart Lung Transplant 2013 Dec 32(12):1147-62.)
pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- 0 (negative)
- 1h
- 1i
- 2
- 3
- Positive for AMR but pAMR score not known

Question Added: 07 OCT 2015
PAMRSCOR

2c.ii AMR Findings
If only accessed histology/ did not perform immunofluorescene or immunohistochemistry (ie. C4d or C3d

- No histologic features AMR
- Positive histologic features AMR (ie. Vasculitis/ pericapillaritis)

Question Added: 07 OCT 2015
BIOPAMR

Rejection Evaluations

Start with newly diagnosed rejection by biopsy (convert to ISHLT score) or other criteria leading to bolus immunotherapy. List all follow-up biopsies or changes in therapy. The last entry should be the first biopsy or echo not prompting additional therapy. Enter each subsequent evaluation event until episode is resolved.

3 Was donor specific Ab testing performed at the time of the rejection evaluation

- Yes
- No, Did not send testing for any circulating antibodies
- Unknown

Question Added: 07 OCT 2015
DABTEST

3a Which antibodies were tested and what were the results

- ☐ HLA class I and/or class II DSA — HLACLASS
- ☐ Isoagglutinin (A or B Ab) to ABO-i graft — ISOAGG
- ☐ Non-HLA antibody (e.g. MICA, MICB, anti-endothelial, vimentin, anti-myosin, angiotensin receptor (AR1T), or other non-HLA — NONHLAAB
- ☐ Unknown — HLAUNK

Question Added: 07 OCT 2015

3a.i HLA Class I and/or II DSA Result

- Negative
- Positive
- Unknown

Question Added: 07 OCT 2015
DABHLANP

3a.i.1 HLA class I and/or II DSA Result, Positive

- ☐ Complement fixing (C1q positive) — DABPC1Q
- ☐ Increased from last date tested — DABPINC
- ☐ New — DABPNEW
- ☐ Present but stable (no new abs and not increased from baseline) — DABPPS
- ☐ Unknown — DABPUNK

Question Added: 07 OCT 2015

3a.ii **Non-HLA Ab Result**
Non-HLA antibody (e.g. MICA, MICB, anti-endothelial, vimentin, anti-myosin, angiotensin receptor (AR1T), or other non-HLA Results

- ○ Negative
- ○ Positive
- ○ Unknown

Question Added: 07 OCT 2015
NONHLANP

3a.ii.1 **Non-HLA Ab Result, Positive**
Non-HLA antibody (e.g. MICA, MICB, anti-endothelial, vimentin, anti-myosin, angiotensin receptor (AR1T), or other non-HLA Results

- ☐ Increased from last date tested — NHLAINC
- ☐ New — NHLANEW
- ☐ Present but stable (no new abs and not increased from baseline) — NHLAPS
- ☐ Unknown — NHLAUNK

3a.iii **Isoagglutinin (A or B Ab) to ABO-i graft**
Positive is defined as titer of 1:16 or higher

- ○ Negative
- ○ Positive
- ○ Unknown

Question Added: 07 OCT 2015
DABISONP

Dataset Name: REJECTIONEVALUATIONS / REJ_EVALUATIONS

Rejection Evaluations

Date of rejection evaluation
Any evaluation leading to an increase in immunotherapy to treat a biopsy or clinically diagnosed episode of rejection
MM/DD/YYYY

4a **Basis for Evaluation**

- ☐ Biopsy — BIOPSY
- ☐ Clinical — CLINIC
- ☐ Echo — ECHO
- ☐ New or increased Abs — NIABS
- ☐ Unknown — BDUNK

Question Added: 01 JAN 1993

4a.i **ECHO features suggesting rejection**
Check all that apply

- ☐ LV dysfunction Mild — ECHOLVDYSMILD
- ☐ LV Dysfunction Moderate — ECHOLVDYSMOD
- ☐ LV Dysfunction Severe — ECHOLVDYSSEV
- ☐ RV Dysfunction — ECHORVDYS
- ☐ New or worsening AV Valve Regurgitation — ECHOAVVALVE
- ☐ Other, specify — ECHOOTHER

4b **Was biopsy performed?**

- ○ Yes
- ○ No

Question Added: 07 OCT 2015
CRBIOP

4b.i **Biopsy Date**

Missing Reason:
- ○ Unknown

BIODT

Question Added: 01 AUG 2022

4b.ii Indication for biopsy
Check all that apply.

- [ ] Objective Evidence of Graft Dysfunction — GDBIOP
- [ ] Research — RESBIOP
- [ ] Routine (scheduled as part of protocol surveillance) — RPBIOP
- [ ] Symptoms — SYMBIOP

Question Added: 01 JAN 2010

4b.iii ACR Grading
2004 revised ISHLT grading system for ACR: (J Heart Lung Transplant. 2005 Nov;24(11):1710-20.)
ACR: acute cellular rejection (0, 1R, 2R, 3R)

- ( ) 0R
- ( ) 1R
- ( ) 2R
- ( ) 3R
- ( ) Unknown

Question Added: 01 JAN 1993
BXSCORE

4b.iiii AMR Grading
2013 revised ISHLT grading system for pAMR: J Heart Lung Transplant 2013 Dec 32(12):1147-62.)
pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- ( ) Both histology and immunofluorescence/ immunohistochemistry performed (ie. C4d or C3d)
- ( ) Did not assess biopsy for evidence of AMR
- ( ) Only assessed histology/ did not perform immunofluorescence/immunohistochemistry (ie. C4d or C3d)
- ( ) Unknown

Question Added: 07 OCT 2015
AMRTEST

4b.iii.1 If both histology and immunofluorescence/ immunohistochemistry performed, indicate pAMR grading
2013 revised ISHLT grading system for pAMR: J Heart Lung Transplant 2013 Dec 32(12):1147-62.)
pAMR: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3)

- ( ) 0
- ( ) 1h
- ( ) 1i
- ( ) 2
- ( ) 3
- ( ) Positive with Unknown Score

PAMR

4b.iii.2 Histology results

- ( ) No histologic features AMR
- ( ) Positive histologic features AMR

AMRHIST

4c Select the therapy used at the time of this evaluation
If no rejection therapy was used, no more rejection evaluations should be entered for this episode.

- [ ] Augmentation of Baseline Immunosuppresion — RJRXAUG
- [ ] ATG or ATGAM — RJALTGS
- [ ] Bortezomib — RJBORT
- [ ] Eculizumab — RJECLZ
- [ ] Immune Adsorption — RJIMMA
- [ ] Immunoglobulin — RJIGG
- [ ] Methotrexate — RJMETH
- [ ] Photopheresis — RJPHOTO
- [ ] Plasmapheresis — RJPLASMA
- [ ] Rituximab — RJRITUX
- [ ] Steroid Taper — RJTSTER
- [ ] Steroids, IV — RJIVSTER
- [ ] Steroids, Oral — RJOSTER
- [ ] Tacrolimus — RJTAC
- [ ] Cytoxan (cyclophosphamide) — RJCYTO
- [ ] Other, specify — RJOMED

RJOMEDSP

☐ None RJRXNONE

Question Added: 01 JAN 1993

4d **Was this evaluation associated with hemodynamic compromise?**

○ Yes
○ No

None - No significant change in cardiac function at the time of rejection
Mild - Worsening of cardiac function detected (decreased ejection fraction, hypotension, EKG changes) not requiring inotropes.
Severe Inotropic support added due to this rejection episode.

HEMCOM

4d.i **Select all the manifestations of hemodynamic compromise that apply**

☐ Mild Dysfunction	HEMCOMMILD
☐ Moderate Dysfunction	HEMCOMMOD
☐ Severe Dysfunction	HEMCOMSEV
☐ Inotropic Support	HEMCOMINO
☐ ECMO	HEMCOMECMO
☐ Other MCS	HEMCOMOTHER
☐ Unknown	HEMCOMUNK

4e **Did possible or known non-adherence contribute to this rejection?**

○ Yes
○ No

Question Added: 01 AUG 2022
READH

5 **Indicate date of the end of the rejection episode**

MM/DD/YYYY

The end of a rejection episode is defined as follows:
The escalation of treatment was concluded for the acute rejection episode.
If rejection is ongoing at the time of death, the death date should be entered as the end date.
A death form should also be completed.

Question Added: 07 OCT 2015
END_DATE

6 **Was the patient taking maintenance immunosuppression at the time of resolution of rejection episode?**

○ Yes
○ No

Question Added: 07 OCT 2015
REJRIT

6a **Baseline immunosuppressive therapy at time of resolution of rejection episode**

☐ Azathioprine (Imuran)	BITAZA
☐ Cyclosporine (Sandimmune, Neoral, Gengraf, CSA, CyA)	BITCYC
☐ Everolimus	BITEVER
☐ Immune globulin	BITIGG
☐ Methotrexate	BITMETH
☐ Mycophenolate (Cellcept, Myfortic)	BITMMF
☐ Prednisone	BITPRED
☐ Rituximab	BITRITUX

☐ Sirolimus (Rapamycin, Rapamune)	BITSIRO
☐ Tacrolimus (Prograf, FK506)	BITTAC
☐ Cytoxan (Cyclophosphamide)	BITCYT
☐ Unknown	BITUNK
☐ Other, Specify	BITOT
	BITOTSP

© 2025 PHTS
[PHTS]